Longboard Pharmaceuticals CEO Kevin Lind's 2022 pay jumps 72% to $1.5M
Longboard Pharmaceuticals reports 2022 executive compensation
By ExecPay News
Published: April 11, 2023
Longboard Pharmaceuticals reported fiscal year 2022 executive compensation information on April 11, 2023.
In 2022, three executives at Longboard Pharmaceuticals received on average a compensation package of $1.3M, a 33% increase compared to previous year.
Average pay of disclosed executives at Longboard Pharmaceuticals
Kevin R. Lind, Chief Executive Officer, received $1.5M in total, which increased by 72% compared to 2021. 38% of Lind's compensation, or $572K, was in salary. Lind also received $378K in non-equity incentive plan, $544K in option awards, as well as $12K in other compensation.
Randall E. Kaye, Chief Medical Officer, received a compensation package of $1.4M. 60% of the compensation package, or $827K, was in option awards.
Brandi L. Roberts, Chief Financial Officer, earned $861K in 2022, a 35% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 11, 2023.